KR20230083291A - 암 치료를 위한 병용 요법 - Google Patents

암 치료를 위한 병용 요법 Download PDF

Info

Publication number
KR20230083291A
KR20230083291A KR1020237013320A KR20237013320A KR20230083291A KR 20230083291 A KR20230083291 A KR 20230083291A KR 1020237013320 A KR1020237013320 A KR 1020237013320A KR 20237013320 A KR20237013320 A KR 20237013320A KR 20230083291 A KR20230083291 A KR 20230083291A
Authority
KR
South Korea
Prior art keywords
cancer
pharmaceutically acceptable
azd5305
acceptable salt
chemotherapeutic agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237013320A
Other languages
English (en)
Korean (ko)
Inventor
엘리자베타 레오
Original Assignee
아스트라제네카 아베
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아스트라제네카 아베 filed Critical 아스트라제네카 아베
Publication of KR20230083291A publication Critical patent/KR20230083291A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020237013320A 2020-10-08 2021-10-07 암 치료를 위한 병용 요법 Pending KR20230083291A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063089195P 2020-10-08 2020-10-08
US63/089,195 2020-10-08
PCT/EP2021/077703 WO2022074124A1 (en) 2020-10-08 2021-10-07 Combination therapy for treating cancer

Publications (1)

Publication Number Publication Date
KR20230083291A true KR20230083291A (ko) 2023-06-09

Family

ID=78293953

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237013320A Pending KR20230083291A (ko) 2020-10-08 2021-10-07 암 치료를 위한 병용 요법

Country Status (19)

Country Link
US (1) US20230372333A1 (cg-RX-API-DMAC7.html)
EP (1) EP4225297B1 (cg-RX-API-DMAC7.html)
JP (1) JP7818585B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230083291A (cg-RX-API-DMAC7.html)
CN (1) CN116194110B (cg-RX-API-DMAC7.html)
AU (1) AU2021356123B2 (cg-RX-API-DMAC7.html)
BR (1) BR112023005160A2 (cg-RX-API-DMAC7.html)
CA (1) CA3197056A1 (cg-RX-API-DMAC7.html)
DK (1) DK4225297T3 (cg-RX-API-DMAC7.html)
ES (1) ES3005507T3 (cg-RX-API-DMAC7.html)
FI (1) FI4225297T3 (cg-RX-API-DMAC7.html)
HU (1) HUE069249T2 (cg-RX-API-DMAC7.html)
IL (1) IL301687A (cg-RX-API-DMAC7.html)
MX (1) MX2023004156A (cg-RX-API-DMAC7.html)
PL (1) PL4225297T3 (cg-RX-API-DMAC7.html)
PT (1) PT4225297T (cg-RX-API-DMAC7.html)
TW (1) TW202228693A (cg-RX-API-DMAC7.html)
WO (1) WO2022074124A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202304965B (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202304911A (zh) * 2021-04-23 2023-02-01 大陸商南京明德新藥研發有限公司 吡啶醯胺類化合物
WO2023036285A1 (zh) * 2021-09-09 2023-03-16 南京奥利墨斯医药科技有限公司 一种杂芳环类化合物及其应用
US20230250428A1 (en) * 2022-02-07 2023-08-10 Alliance Of Cardiovascular Researchers Method and composition for early detection of malignancies
IL316019A (en) * 2022-04-07 2024-11-01 Astrazeneca Ab Combined treatment for cancer
CA3254948A1 (en) * 2022-04-07 2023-10-12 Astrazeneca Ab Polytherapy for the treatment of cancer
CN121464135A (zh) * 2023-07-07 2026-02-03 优领医药科技(香港)有限公司 含哌嗪并环类衍生物的晶型、其盐型、其制备方法及应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6648040B2 (ja) * 2014-05-28 2020-02-14 エーザイ・アール・アンド・ディー・マネジメント株式会社 がん治療のための併用療法としてのエリブリン及びポリ(adpリボース)ポリメラーゼ(parp)阻害剤の使用
TWI837403B (zh) * 2019-07-19 2024-04-01 瑞典商阿斯特捷利康公司 化學化合物

Also Published As

Publication number Publication date
HUE069249T2 (hu) 2025-02-28
ES3005507T3 (en) 2025-03-14
DK4225297T3 (da) 2025-01-02
PT4225297T (pt) 2024-12-30
EP4225297A1 (en) 2023-08-16
JP2023546362A (ja) 2023-11-02
FI4225297T3 (fi) 2024-12-10
US20230372333A1 (en) 2023-11-23
WO2022074124A1 (en) 2022-04-14
AU2021356123B2 (en) 2025-01-09
CA3197056A1 (en) 2022-04-14
EP4225297B1 (en) 2024-10-23
ZA202304965B (en) 2024-09-25
TW202228693A (zh) 2022-08-01
CN116194110B (zh) 2025-06-17
PL4225297T3 (pl) 2025-03-17
CN116194110A (zh) 2023-05-30
MX2023004156A (es) 2023-05-03
IL301687A (en) 2023-05-01
AU2021356123A1 (en) 2023-06-08
BR112023005160A2 (pt) 2023-04-18
JP7818585B2 (ja) 2026-02-20

Similar Documents

Publication Publication Date Title
AU2021356123B2 (en) Combination therapy for treating cancer
JP6664385B2 (ja) Bub1阻害薬としてのベンジル置換インダゾール類
CN107949557B (zh) 作为mIDH1抑制剂的2-芳基-和2-芳烷基-苯并咪唑类
EP2131840B1 (en) Combination of benzimidazole anti-cancer agent and a second anti-cancer agent
ES2895365T3 (es) Pirimidopirimidinonas útiles como inhibidores de la quinasa Wee-1
EA032530B1 (ru) 4h-пирроло[3,2-c]пиридин-4-оновые производные
CN105452236A (zh) 取代的苄基吡唑
CA2806324A1 (en) Phthalazinone ketone derivative, preparation method thereof, and pharmaceutical use thereof
JP2023545096A (ja) 抗体-薬物コンジュゲート及びparp1選択的阻害薬の組み合わせ
CN103534250B (zh) 用于治疗免疫障碍的被取代的吲哚衍生物
CN113348165A (zh) 用于治疗过度增殖性疾病的1,2,4-三嗪-3(2h)-酮化合物
AU2012257345A1 (en) Substituted indole derivatives for the treatment of immunological disorders
EP3233839B1 (en) Heterocyclyl linked imidazopyridazine derivatives as pi3kbeta inhibitors
JP6234450B2 (ja) 5−[5−フェニル−4−(ピリジン−2−イルメチルアミノ)キナゾリン−2−イル]ピリジン−3−スルホンアミドのホスホロアミド酸プロドラッグ
US20100098691A1 (en) Combination of benzimidazole anti-cancer agent and a second anti-cancer agent
WO2020225077A1 (en) Pyrimido[4,5-b]indol derivatives as pdhk1 inhibitors
EA049465B1 (ru) Комбинированная терапия для лечения рака
HK40099137B (en) Combination therapy for treating cancer
HK40099137A (en) Combination therapy for treating cancer
CN114787162A (zh) 取代的咪唑并喹喔啉化合物及其应用
BR122024006404A2 (pt) Compostos inibidores de tirosina e de cdc2 específica de treonina cinase e composição farmacêutica compreendendo os mesmos
CN120904168A (zh) 第四代egfr抑制剂、及其制备方法和在药学上的应用
KR20150079665A (ko) 치환된 인돌 유도체
AU2024341981A1 (en) Parp1 inhibitors and the use in the treatment of cns diseases
CN121045188A (zh) 1,2-二氢吡咯并[1,2-a]吡嗪-3(4H)-酮衍生物及其用途

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902